Crossmark

Whole blood microRNAs as potential biomarkers in post-operative early breast cancer patients

Crossref DOI link: https://doi.org/10.1186/s12885-018-4020-7

Published Online: 2018-02-06

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

,

Alunni-Fabbroni, Marianna http://orcid.org/0000-0002-9710-1662
Majunke, Leonie

Trapp, Elisabeth K.

Tzschaschel, Marie

Mahner, Sven

Fasching, Peter A.

Fehm, Tanja

Schneeweiss, Andreas

Beck, Thomas

Lorenz, Ralf

Friedl, Thomas W. P.

Janni, Wolfgang

Rack, Brigitte
More Information

Article History

Received: 2 February 2017

Accepted: 22 January 2018

First Online: 6 February 2018

Ethics approval and consent to participate

: The study was approved by all the involved ethical boards (lead ethical board: Ludwig-Maximilians-University Munich) and conducted in accordance with the Declaration of Helsinki. All patients and healthy donors provided written informed consent.

: Not applicable

: In frame of the SUCCESS A clinical trial, BR, WJ, AS, PAF received research funding and/or speaker honoraria from AstraZeneca, Chugai, Lilly, Novartis, Sanofi-Aventis and Janssen Diagnostics. MA-F, TB, RL, TF, TWPF, LM, SM, EKT and MT have no competing interest to declare.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.